Then, BTZ naïve and resistant myeloma cell lines were treated with SHP099 or RMC-4550 for 48 h, and we found that SHP2 inhibitors were effective despite a relatively lower level of p-SHP2 in BTZ-resistant MM cells than that in BTZ naïve MM cells (Figure 8C,D). This evidence concerns the gene PTPN11 and plasma cell myeloma.